Oxford Nanopore Technologies has launched a new Pharmacogenomics (PGx) Beta Program with Twist Biosciences.
The partnership with Twist means Oxford Nanopore will have access to Twist's next-generation sequencing (NGS) "target enrichment technology" for long-read sequencing. Twist’s library preparation reagents and target enrichment panels will be integrated with Oxford Nanopores’ MinION and PromethION flow cells.
Oxford Nanopore said the PGx beta program has successfully achieved full resolution of the CYP2D6 gene in a single assay. This gene is responsible for metabolizing 20% of drugs on the market and is one of the most challenging genes to sequence due to its complex structure, according to the company.
"The Twist Alliance Long-Read PGx Panel coupled with Chinook, Oxford Nanopore’s CYP2D6-specific allele caller, demonstrated 100% CYP2D6 reference concordance, overcoming the limitations of conventional sequencing technologies," Oxford Nanopore said. The newly unveiled Twist-Oxford Nanopore long-read PGx solution is available for research use only.
